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Objectives: In this study, an efficient and fast method has been developed for 
synthesis of a novel magnetite nanoparticles Fe3O4@SiO2@Gold as an efficient 
boronated nanodrug carrier. Application and characterization of core-shell iron 
oxide (Fe3O4/γ-Fe2O3) magnetic nanoparticles (MNPs) with an inner silica shell 
and outer of Gold shell (Fe3O4-SiO2@Gold (FSG)) in Boron Neutrons Capture 
Therapy (BNCT) highlighted. The main problem dealing with cancer cells is 
that the tumor and normal cells ones are mixed without a map of the boron 
accumulation.
Methods: The content of the discussion include the possibility of a FSG 
mediated by liposome as the boron carriers for the transfer of boron compound 
to tumor tissue. Furthermore, folate receptor was considered as an appropriate 
substrate that has great potential to attach to tumor. The present work aimed to 
study boron biodistribution in the muscle cancer animal model in Bagg Albino 
(BALB/c) mice employing PEGylated liposome-encapsulated FSG formulations.
Results: The predetermined boron concentration was obtained to be 20-35 
mg 10B/g. Samples of the tumor tissue, such as kidney, liver, lung, heart, skin, 
spleen, brain, stomach, and bone were taken as post-administration at different 
times to measure boron content by Inductively Coupled Plasma (ICP) analysis. 
The results showed the existence of GLUT-5 expression as an erythrocyte-type 
glucose transporter protein in a wide variety of tumor cells.
Conclusions: Fe3O4-SiO2 nanoparticles are highly biocompatible with biological 
materials and also Gold shell exposes the magnetic properties. 
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INTRODUCTION
In the past decade, magnetic micro and 
nanoparticles have attracted much attention 
because of their unique magnetic properties and 
widespread application in different fields. Magnetic 
nanoparticles are efficient, and readily available, 
and have high surface-area resulting in high 
catalyst loading capacity [1], chemical sensing 
[2-6], information storage [7, 8] and medical 
diagnostics [9–11] and outstanding stability to 
heterogeneous supports for catalysts preparation. 
Accordingly, the application of magnetic nano 
particles has become an interesting filed of research 
besides other advantages of nano particles [12, 13]. 
A series of functionalized magnetic nanoparticles 
(MNPs) involves iron oxide (Fe3O4/γ-Fe2O3) 
magnetic nanoparticles coated with silica and Gold 
shells. [14]. Importantly, Core-shell nanoparticle 
provides both enhanced biocompatibility and 
stability of the surface and imparts the surfaces 
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with the desired biological or chemical, catalytic 
interfacial reactivities [15, 16]. The successes of 
these synthetic approaches  discover  the potential 
applications of FSG [17-20]. 
In pharmaceutical and medical aspects, 
novel drug delivery systems such as polymers, 
liposomes, and Monoclonal antibodies open 
new views in cancer treatment [21]. Traveling of 
Magnetic nanoparticles, such as Fe3O4-SiO2 core-
shell through the bloodstream and tendency to 
accumulate into  the surrounding  tumor tissue 
is important. [22]. One significant aspect is the 
development of compounds that can deliver a 
high boron payload to the tumors [23]. Hence, 
considerable successes have been obtained on the 
liposomal delivery system as a new targeting fact. 
Liposomes are profitable drug delivery carriers 
that are able to selectively transfer a large amount of 
a broad variety of 10B agents to the tumor tissue. For 
this purpose, for carrier system development, folate 
receptors was considered as an appropriate substrate 
that has a potential to attach to tumor compared 
with normal cells. During the investigation of its 
applicable behavior, we have found that the muscle 
cancer in BALB/c mice model possesses a unique 
advantage for treatment of tumors [24-27].
The main problem dealing with muscle cancer is 
that the tumor and normal cells are mixed without 
a map of the boron accumulation. As a result, in 
different tissue samples, the boron concentration 
in tissue composition is not accurate. The purpose 
of study was to perform biodistribution studies of 
FSG in the muscle cancer in BALB/c mice model. 
In this model, we have examined different sites 
surrounding healthy organs in the BALB/c mice 
model. The optimization of selective boron delivery 
to cancer cells is an interesting area of research 
and must be as a starting point to contribute and 
optimize its therapeutic efficacy. Using a novel 
drug containing 10B compound in smart release 
and administering to a patient is a novel method in 
the treatment of the cancerous tumors. The reduce 
production cost as well as minimum side effects in 
treatment are other advantages of the applied drug 
and method.
In the present article, 41.1 mg of the liposome-
encapsulated FSG was delivered to a tumor site. 
Results demonstrated that the highest concentration 
of drug in the tumor tissue (27 mg/L) occurs at a 
period of 45 min to 3 h. Hence, Specific method 
of inductively coupled plasma (ICP) analysis was 
applied for samples of the tumor, normal (muscle) 
tissue, liver, heart, lung, spleen, skin, stomach, 
brain, bone, kidney and blood to check the boron 
distribution in different tissue portions.
MATERIALS AND METHODS
Preparation of Fe3O4-SiO2@Gold (FSG) nanoparticles
Preparation of the Fe3O4 nanoparticles (FMNs)
Fe3O4 nanoparticles were synthesized using a 
modified protocol. FeCl3 and FeCl2 solution in HCl 
with the optimum mole fraction ratio of Fe3+: Fe2+ 
in 2:1 (Fig. 1) was added to a flat bottom balloon 
separately and stirred using a magnetic stirring bar. 
To prepare water-soluble and dispersed FMNs, 
the solutions of FeCl3.6H2O (1 M) and FeCl2.4H2O 
(2 M) were prepared by dissolving the iron salts in 
2 and 1 M HCl solutions in a 250 ml flask. Then, 
the solutions were mixed at 25 °C. Then, ammonia 
solution (1 M, 100 ml) was added droplet. Then, 
particles were filtered and washed several times. 
The pH of the solution was adjusted up to 10. The 
stirring of the solution was continued for 1 h until 
the stable black FMNs were appeared. The ferrite 
powder was finally dried in vacuum oven at 80 °C 
for 24 h to complete removal of water. The reaction 
mechanism is explained as below.
2
3 2 3 4 4Fe 2Fe 8NH H O Fe O NH OH
+ ++ + + → +
Preparation of the Fe3O4/SiO2 magnetic nanoparticles 
(FSMNs)
The core/shell Fe3O4@SiO2 was prepared 
according to the Stober process [28] with some 
modifications. The obtained MNPs powder (1g) 
were dispersed in a mixture of 100 mL of ethanol, 
Fig. 1. Optimization of Fe3+ / Fe2+ ratio for production of Fe3O4
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20 mL of distilled water by the ultrasonic treatment 
for 30 min and 5.0 mL of 28 wt % concentrated 
ammonia aqueous solution (NH3.3H2O) with 
vigorous stirring, followed by the addition of 2 mL 
of Tetra Ethyl Ortho Silicate (TEOS) was dropwise 
added to this dispersion. The resulting dispersion 
was kept stirred mechanically under N2 protection 
for 12 h at room temperature. The obtained Fe3O4@
SiO2 nanoparticles were separated with a magnet 
and washed repeatedly with ethanol and water to 
remove nonmagnetic byproduct. 
Activation of FSMNs
Then, the obtained MNPs powder (1g) was 
dispersed in methanol (100 mL) and toluene (30 
mL) by the ultrasonic treatment for 30 min before 
3-Amino Propyl Tri Ethoxy Silane (APTES), (99%, 
1 mL) was added to the mixture. After mechanically 
agitation for 12 h, the suspended substance was 
separated by a magnet. The settlement product 
was redispersed in ethanol by sonication and 
isolated with magnetic decantation for 5 times. The 
precipitated product (APTES-MNPs) was dried at 
room temperature under vacuum. The reactions 
mechanism is explained as below.
2 3 4 3 4 4 2FeC 2Fec 8NH OH Fe O 8NH c 4H Ol l l+ + → + +
3 4 2 3 4Fe O .nc H O Fe O OH nc Hl m m l m
− − − ++ → + +
( ) ( )2 5 2 2 54OC H H O OH C H OHSi Si+ → +
Preparation of Fe3O4-SiO2@Gold nanoparticles
The synthesis of Fe3O4  nanoparticles starts 
according to process in which Fe(acac)3 is reduced 
using 1,2-hexadecanediol in the presence of oleic 
acid. Following Fe3O4 make as nanoparticles with 
the favorite sizes, Gold is deposited on to the surface 
of Fe3O4  by reduction of Au(CH3COO)3  using 
1,2-hexadecanediol in the presence of oleic 
acid at higher temperature (180–190 ºC). The 
resulting Fe3O4-SiO2@Gold  nanoparticles  can be 
separated by centrifugation from the uncoated 
Fe3O4 nanoparticles. 
This approach can produce highly monodisperse 
Fe-oxide-SiO2-Gold nanoparticles.
Synthetic procedure of liposome-encapsulated FSG
The synthetic procedure of liposome-
encapsulated FSG using polyethylene glycol (PEG) 
as a precursor mentioned in the literature [29] 
allows a solubility of the drug in the blood and 
binding of a ligand to the liposome. Furthermore, 
folate ligand bonded to the PEG. As demonstrated 
in Fig. 3, the liposome can encapsulate aqueous 
solutions of sodium salts anions and join lipophilic 
boron-containing nanodrug components embedd-
ed within the bilayer membrane [30]. For this 
purpose, 1 M solution of fructose in water or ethanol 
and 1 M solution of boric acid containing 10Boron 
were provided. Also, adjusting and controlling 
the solution pH around 3-4 was performed. Then, 
some carbonate salt of solid calcium (dissolved in 
a little amount of deionized water) was added to 
the solution. As a result of this process, the biphasic 
solution was formed and the lower phase was 
separated. Nanodrug has several boron atoms in 
each molecule that caused to easily penetrate to the 
membrane of the tumor cell.
Model of cancer: Biodistribution and boron analysis 
studies
The digestion of animals samples was carried 
out according procedure as discussed in the 
Fig. 2. Step 1: An illustration of the Fe3O4 magnetic nanoparticles and synthesis of the Fe3O4-SiO2 magnetic nanoparticles. Step 2: 
Schematic process of producing the core – shell Fe3O4-SiO2@Gold nanoparticles
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literature [31].  Over time, to identify the optimal 
injection protocol for delivery of boron to the 
tumor tissue, performed experiments were 
analyzed. Following the appropriate experiments, 
the data were presented and boron concentration 
was individually analyzed. 
In the present study, several samples of tumor 
and cancerous tissues around tumor tissues 
were taken from each animal to informant the 
distribution of boron in the tumor, blood, and 
normal tissues [32]. Boron concentration values 
in the tumor, blood, and normal (muscle) tissues 
were obtained as post-administration to calculate 
the ratio of boron concentration in tumor/blood, 
normal tissue/blood and tumor/normal tissue for 
each of the compounds [33]. Fig. 4 shows an overall 
schematic of the entrance process of the drug and 
the process of BNCT used in the prior investigation.
RESULTS AND DISCUSSION
In order to investigate the morphology and 
the structure of FSG nanoparticle, the prepared 
particles were analyzed.
Qualitative and Quantitative Analysis
XRD analysis of FSG nanoparticles
X-ray diffraction pattern (JCPDS, card number 
01-072-1243) for the (a) Fe3O4 nanoparticles (b) 
Fe3O4-SiO2 nanoparticles (c) Fe3O4-SiO2@Gold 
Fig. 3. Schematic of liposome-encapsulated FSG
Fig. 4. Overall schematic of the nanodrug entrance into the blood and tissue
Fig. 5. X-ray diffraction pattern for the (a) Fe3O4 nanoparticles 
(b) Fe3O4-SiO2 nanoparticles (c) Fe3O4-SiO2@Gold nanoparticles
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nanoparticles showed in Fig. 5. The XRD pattern 
showed the characteristic peaks at 2θ of 9.2◦, 11◦, 
31.8◦, and 45.4◦ and the size of Fe3O4 nanoparticles 
obtained was 9.80 nm. Furthermore, the data 
showed diffraction peaks at 2θ° = 38.2°, 44.2°, 
64.5°, 77.8°, and 81.7°, which can be indexed to 
planes of Gold.
FTIR analysis of FSG nanoparticles
The reactions  were confirmed  using the FTIR 
analysis. The FTIR spectra of (a) Fe3O4 nanoparticles 
(b) Fe3O4-SiO2 nanoparticles and (c) Fe3O4-SiO2@
Gold nanoparticles showed in Fig. 6. In contrast 
to the spectrum of  Fe3O4-SiO2 nanoparticles, the 
spectrum of the  Fe3O4-SiO2@Gold nanoparticles 
shows a bond at 3400 cm-1, that could be assigned 
to N-H stretching. The bonds at 1020 cm-1  also 
could be attributed to the stretching of C-H groups 
of  alkyls  in the  Fe3O4-SiO2@Gold nanoparticles. 
The magnetite spectrum shows a bond at 573 cm-
1, that could be assigned to magnetite vibrations. 
The bonds at 3440 cm-1  also could be attributed 
to the stretching of O-H groups of  hydroxyls  in 
the magnetic nanoparticles. Furthermore, the bonds 
at 1614 and 1391 cm-1 that appeared in the spectrum 
of the Fe3O4-SiO2 nanoparticles could be attributed 
to formation of carboxyl group bond to Fe3O4 
in Fe3O4-SiO2 nanoparticles. In addition, the bonds 
Fig. 6. The FTIR spectra of (a) Fe3O4 nanoparticles (b) Fe3O4-
SiO2 nanoparticles (c) Fe3O4-SiO2@Gold nanoparticles
Fig. 7. The TEM image of (a) Fe3O4-SiO2@Gold nanoparticles and (b) Fe3O4-SiO2 nanoparticles
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at 1621, 1091 and 955 cm-1 could be attributed to 
H-O-H stretching, Si-O-Si stretching and Si-OH 
stretching in magnetite-silica nanoparticles.
TEM study of FSG nanoparticles
TEM data supports Fe3O4-SiO2@Gold core shell 
nanoparticles forms. There are two major findings 
from the morphological comparison. Firstly, the 
particles after coating with Silica and Gold seem 
much darker and secondly, for the particles after 
coating with SiO2 and Gold, the average particle 
size changed from 9.8 nm to 15 nm. In Fig. 6, the 
TEM data prepare an important piece of evidence 
for Fe3O4-SiO2@Gold core-shell forms.
Biodistribution and boron analysis studies: in-vivo 
and in-vitro treatment
In this section, the experiments conducted 
which were related to in-vivo and in-vitro 
conditions of the biological tests. Studying the 
effects of drug-containing 10B on the muscle cancer 
and the corresponding Dose-Responses curves 
were performed. The predetermined concentration 
was 20-35 mg  10B/g. The experiments were 
performed dealing with the biological distribution 
of the designed drug in different times of injection, 
biological distribution of various doses of the drug 
and sufficient accumulation of the designed drug-
containing 10Boron aiming influential treatment of 
the tumor.
As mentioned above, the drug with concentrations 
of 15, 25, 35 and 45 mg was selected to inject to the 
animal. The results of ICP data indicate that the 
drug concentration of 35 mg into the cell culture 
medium maximized the accumulation of the drug 
within 24 h incubation of the drug introduced 
to the environment (Fig. 8). The reason can be 
attributed to the representation of the toxicity of 
the synthesized composition using MTT assay 
method.
Fig. 8. Optimum boron concentrations (µg) vs treatment time, ICP for the drug
Fig. 9. Diagram of toxicity for in-vivo treatment in animal
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To perform in-vivo treatment in testing animal, 
the toxicity of the liposome-encapsulated FSG was 
analyzed. Fig. 9 shows the diagram of toxicity of the 
liposome-encapsulated FSG determined by MTT 
assay method [34]. 
As can be seen, in the initial time, the number 
of live cells is not considerably changed; because of 
using the unit dietary compound to drug synthesis. 
While with respect to time, the number of tumor 
cells is gradually decreased. After 24 h, these 
reductions were 79, 64, 50, 80 and 36 % for various 
boron compounds at concentrations of 5, 10, 25, 50 
and 100 mg/L, respectively. After 48 h, the results 
were similar to those obtained after 24 h with a 
slight differences [35].
Boron biodistribution studies were essential to 
preclinical design and subsequent clinical research 
protocols of BNCT. In particular, this analysis 
identifies the optimum time post-administration of 
the boron carrier to perform neutron therapy [36]. 
To date, dose calculations were based on boron 
content values in blood, tumor, and normal tissues 
obtained beforehand from biodistribution studies. 
in the case of animal models, calculations were based 
on the mean values obtained from biodistribution 
studies in separate portions of tissues [37]. The 
tabulated diagrams and data corresponding to the 
mean value ± standard deviation of the ratio for 
each sample are shown in Fig. 10.
The results showed that the highest concentration 
of drug in the tumor tissue occurred at a period 
of 45 min to 3 h. Also, after drug injection, its 
concentration initially in the blood reached to the 
highest value; while it may reach to the lowest value 
within 24 h [38].
Generally, the results of boron concentration 
in the tumor tissue showed that after 3 h of drug 
injection to the tumor, the drug concentration 
reached to its highest level (27 mg/L) due to the 
excessive amount of sugar transmitters such as 
GLUT5 in the tumor cells. It can be concluded that 
the transfer of FSG was carried out by the GLUT5 
transmitter to the tumor [39]. Since, the number of 
these transmitters in the cancerous tissue is greater 
Fig. 10. Boron concentration in blood, normal tissue and tumor tissue for drug with respect to time
Fig. 11. Boron concentration in several tissue samples for the drug with respect to time (h)
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than other tissues, selective accumulation of drug 
in the cancerous tissue occurred. 
The drug concentration in the tumor tissue 
increased with respect to time due to the drug 
release to the tumor tissue through the blood [40]. 
With the accumulation of drug in the tumor, its 
concentration increased after 6 h of injection due 
to the sugar consumption of the drug by tumor 
cells and then, the amount of boron in the tumor 
tissue reduced. These results were consistent with 
the results obtained by other researchers regarding 
the excessive amount of sugar transmitters in 
tumor tissue [41]. Furthermore, Table 1 shows the 
absolute boron concentration values for the blood, 
tumor and normal tissues. The boron concentration 
(BC) in the blood, compared with normal tissue, is 
often used as the cited phrase to calculate the BC 
in the tumor for BNCT. By injecting the drug, its 
concentration in the blood reached to the highest 
value at initial time, and by transferring drug to 
other tissues and organs at long duration of time, 
its concentration ultimately decreased and reached 
to the lowest level within 24 h after injection [42]. 
In this article, the ratio of BC in normal tissue to 
that in blood, i.e. N/B ratio, remains about ~1.6 at 
45 min post-administration [43].
Fig. 11 shows a graphical representation of the 
biodistribution of the  10B-drug in different tissues 
of the model of the animal body at different time, 
after injection (41.1 mg of 10Boron complex per 
every 30 g of the animal weight). The concentration 
of boron in the kidneys tissue initially increased 
and reached to the highest value of 17 mg/L within 
3 h after injection. The kidneys contain glomeruli 
that are blood filters. Hence, these data are 
consistent with the results of Edward’s study that 
highlights the expression of GLUT5 in the kidney 
glomerular tissue. In liver tissue, the accumulation 
of the drug reached to the highest value. The results 
of the ICP analysis for heart tissue were similar 
to the results obtained for normal tissue due to 
the muscular structure of the heart. The results 
of drug distribution studies on spleen and lung 
tissues were interesting. Furthermore, the results 
show that the drug concentration was high at 
initial time after injection to the lung and spleen 
tissues due to the high rate of blood donation in the 
tissues. With respect to time, it is observed that the 
concentration of drug in the tissues significantly 
reduced and reached to its minimum value (2 
mg/L) within 24 h. The concentration of the drug in 
the skin tissue at the initial time has reached to the 
highest value and then, rapidly reduced to 1.5 mg/L 
for duration of 3 h. This result can be attributed to 
the high distribution of blood capillary network 
inside the skin tissue [44]. At the initial time after 
injection, the concentration of boron in the skin 
tissue increased and then, decreased with respect 
to time with blood circulation. The study of drug 
concentration in stomach tissue shows its highest 
concentration after 3 and 6 h of injection and then, 
follows descending trend to the value of 4 mg/L 
within 24 h after injection. The reason for high 
concentrations of boron in the stomach tissue can 
be attributed to its muscle structure and high blood 
donation at a time interval of 3 to 6 h. The highest 
amount of boron in the brain tissue occurred 
within 3 h after injection. The concentration of 
boron in the bone tissue increased to 10 mg/L after 
3 h with a high rate.
Considering high importance of the tissues in 
the case of breast cancer, it can be concluded that 
the mean concentration of boron considerably 
decreased and its value falls within the range of 6 
to 10 mg/L, similarly for tumor, lung, spleen, and 
skin tissues.
CONCLUSIONS
There are many challenging issues for 
the application and characterization of the 
detailed core-shell FSG nanostructures. Results 
demonstrated that the coupling of the biological 
and catalytic interfacial reactivity and the 
magnetic activity of core-shell nanoparticles is 
an effort to  further broaden the rapidly-emerging 
field  of  core@shell magnetic. In this study, the 
time-course biodistribution of boron delivered 
by liposome-encapsulated FSG in the BALB/c 
Ratio 
Time (h) after administration 
0 0.75 1.5 3 6 12 24 
T/N 0.33 0.37 0.91 1.81 3.37 4.29 1.05 
T/B 0.55 0.59 1.09 3.59 3.17 3.43 2.69 
N/B 1.68 1.59 1.20 1.98 0.94 0.80 2.55 
T: Tumor; N: Normal tissue (muscle); B: Blood;  
 
Table 1. T/N, T/B, and N/B boron concentration ratios in mice administration FSG
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mice muscle cancer model was reported for the 
first time. In summary, it was demonstrated 
that the combined administration of FSG offers 
the most similarity in practicable targeting of 
different tumors; because of these boron carriers 
have different uptake mechanisms and properties. 
Furthermore, it was possible to selectively transfer 
the amounts of therapeutic boron to BALB/c mice 
tumor and achieve ratios between tumor and blood 
that was compatible with the treatment. The results 
of ICP data indicated that the drug concentration 
of 35 mg in the cell culture medium maximized 
the accumulation of the drug for 24 h incubation 
after the drug introduced to the environment. Also, 
the highest concentration of drug (27 mg/L) in the 
tumor tissue occurs at a period of 45 min to 3 h 
due to the excessive amount of sugar transmitters 
such as GLUT5 in the tumor cells. In summary, the 
results of the present study demonstrated that the 
therapeutic potential of boron-bearing liposomes 
led to large boron biodistribution values [45-50]. 
The results can be considered as a guideline for 
further understanding boron targeting processes 
associated with the agents studied. 
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